{"company":{"id":2500256,"name":"UroGen","domain":"urogen.com","url":"https://alion.io/company/urogen"},"section":"news","answer":"UroGen: 23 headlines on record, 7 headlines in the last 90 days.","figures":[{"label":"Headlines","value":"23"},{"label":"In 90 days","value":"7"},{"label":"Milestones","value":"0"}],"blocks":[{"key":"news","title":"Headlines","source":"the outlets named on each headline, each story once","rows":20}],"news":[{"date":"2026-10-21","kind":"News","title":"Why UroGen Pharma (URGN) Is Getting Fresh Attention Now","source":"YahooFinance","url":"https://finance.yahoo.com/healthcare/articles/why-urogen-pharma-urgn-getting-221748366.html"},{"date":"2026-10-19","kind":"News","title":"UroGen Announces FDA Acceptance of the New Drug Application for UGN-103, an Investigational Treatment for Adults with Recurrent LG-IR-NMIBC","source":"markets.businessinsider.com","url":"https://markets.businessinsider.com/news/stocks/urogen-announces-fda-acceptance-of-the-new-drug-application-for-ugn-103-an-investigational-treatment-for-adults-with-recurrent-lg-ir-nmibc-1036638675"},{"date":"2026-10-19","kind":"News","title":"UroGen Pharma Says FDA Accepts New Drug Application for UGN-103 in Bladder Cancer","source":"YahooFinance","url":"https://finance.yahoo.com/healthcare/articles/urogen-pharma-says-fda-accepts-130749194.html"},{"date":"2026-10-13","kind":"News","title":"UroGen Pharma: An Emerging GARP Stock","source":"seekingalpha.com","url":"https://seekingalpha.com/article/4953717-urogen-pharma-an-emerging-garp-stock"},{"date":"2026-09-04","kind":"News","title":"UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","source":"markets.businessinsider.com","url":"https://markets.businessinsider.com/news/stocks/urogen-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-1036522662"},{"date":"2026-08-20","kind":"News","title":"Cancer treatment co UroGen invests $7m in Israel's IntraGel","source":"en.globes.co.il","url":"https://en.globes.co.il/en/article-urogen-invests-7m-in-israels-intragel-therapeutics-1001553029"},{"date":"2026-08-05","kind":"News","title":"Listen to webcast","source":"edge.media-server.com","url":"https://edge.media-server.com/mmc/p/97d85f7g"},{"date":"2026-07-01","kind":"News","title":"Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Let Go of 10,000 Shares?","source":"The Motley Fool","url":"https://fool.com/coverage/filings/2026/06/30/is-urogen-pharma-a-stock-to-sell-after-its-chief-medical-officer-let-go-of-10-000-shares/"},{"date":"2026-05-13","kind":"News","title":"UroGen Pharma Ltd 2026 Global Healthcare Conference","source":"kvgo.com","url":"https://kvgo.com/2026-may-global-healthcare-conference/urogen-pharma-ltd"},{"date":"2026-05-06","kind":"News","title":"UroGen outlines ZUSDURI path to \"peak annual revenues exceeding $1 billion\" while holding 2026 operating expense guidance at $240M-$250M","source":"seekingalpha.com","url":"https://seekingalpha.com/news/4587819-urogen-outlines-zusduri-path-to-peak-annual-revenues-exceeding-1-billion-while-holding-2026"},{"date":"2026-04-21","kind":"News","title":"UroGen Pharma - Right Patient, Right Treatment: Real-World Insights on ZUSDURI(mitomycin) for Intravesical Solution","source":"LifeSci Events","url":"https://lifescievents.com/event/kfw04gs3/"},{"date":"2026-03-10","kind":"Press release","title":"UroGen Pharma Earnings Call: Launch Momentum Meets Rising Costs","source":"The Globe and Mail","url":"https://theglobeandmail.com/investing/markets/stocks/URGN/pressreleases/652680/urogen-pharma-earnings-call-launch-momentum-meets-rising-costs/"},{"date":"2026-03-02","kind":"News","title":"PRN_FinancialWrapper","source":"PRNewswire","url":"https://markets.financialcontent.com/prnews/article/gnwcq-2026-3-2-urogen-announces-zusduri-launch-is-on-track-and-reports-fourth-quarter-and-full-year-2025-financial-results"},{"date":"2025-12-26","kind":"News","title":"Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally","source":"The Motley Fool","url":"https://fool.com/coverage/filings/2025/12/26/billionaire-family-office-dumps-all-of-its-urogen-stock-amid-100-rally/"},{"date":"2025-11-02","kind":"News","title":"UroGen: Expect Rough Patch Before Strong Recovery In 2026","source":"seekingalpha.com","url":"https://seekingalpha.com/article/4836758-urogen-expect-rough-patch-before-strong-recovery-in-2026"},{"date":"2025-06-13","kind":"News","title":"UroGen's Zusduri wins FDA's blessing as first therapy for certain bladder cancer patients, despite negative adcomm vote","source":"fiercepharma.com","url":"https://fiercepharma.com/pharma/urogens-zusduri-wins-fdas-blessing-first-therapy-certain-bladder-cancer-patients-despite"},{"date":"2025-06-03","kind":"Press release","title":"Law Offices of Frank R. Cruz Encourages UroGen Pharma Ltd. (URGN) Investors To Inquire About Securities Fraud Class Action","source":"businesswire","url":"https://businesswire.com/news/home/20250603937922/en/Law-Offices-of-Frank-R.-Cruz-Encourages-UroGen-Pharma-Ltd.-URGN-Investors-To-Inquire-About-Securities-Fraud-Class-Action"},{"date":"2025-05-07","kind":"News","title":"UroGen Announces FDA Advisory Committee for UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer","source":"streetinsider.com","url":"https://streetinsider.com/Business+Wire/UroGen+Announces+FDA+Advisory+Committee+for+UGN-102%2C+an+Investigational+Treatment+for+Recurrent+Low-Grade+Intermediate-Risk+Non-Muscle+Invasive+Bladder+Cancer/24754417.html"},{"date":"2025-02-19","kind":"Press release","title":"UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations","source":"businesswire.com","url":"https://businesswire.com/news/home/20250220875021/en/UroGen-Advances-Long-Term-Growth-Strategy-by-Acquiring-a-Next-Generation-Investigational-Oncolytic-Virus-ICVB-1042-and-Announces-Multiple-Strategic-Research-Collaborations/"},{"date":"2024-04-15","kind":"Press release","title":"UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle ...","source":"businesswire.com","url":"https://businesswire.com/news/home/20240415706532/en/UroGen-Announces-FDA-Acceptance-of-Investigational-New-Drug-Application-for-UGN-103-a-Next-Generation-Mitomycin-Based-Formulation-for-Low-Grade-Intermediate-Risk-Non-Muscle-Invasive-Bladder-Cancer"}],"as_of":"2026-11-16","cite":"UroGen, News. Alion, Nov 16, 2026. https://alion.io/company/urogen/news","html_url":"https://alion.io/company/urogen/news","json_url":"https://alion.io/company/urogen/news.json","license":"CC BY-SA 4.0","meta":{"source":"Alion","generated_at":"2026-11-16T00:14:54Z"}}